CORONA Remedies quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Year before	Change
Revenue	422	—	—
EBITDA	93.1	—	—
EBITDA margin	22.1%	—	—
Profit before tax	80.4	—	—
Net profit	60.1	—	—
EPS	₹9.83	—	—

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025

Expenses
	422	353	342	361
	3.2	4.1	2.2	2.3
	426	357	345	363
	32.7	27.7	24.8	25.9
	57.2	46.3	41.2	28.1
	−12.3	−7.8	−5.7	14.6
	122	107	95.9	103
	2.7	1.4	1.7	1.9
	13.2	10.3	9.5	9.2
	130	118	103	111
	345	303	270	294
	93.1	62.0	83.2	78.5
	79.9	51.7	73.7	69.3
Profit
	80.4	54.5	74.3	69.6
	0.0	0.3	−19.1	0.0
	80.4	54.7	55.2	69.6
	18.4	4.2	17.1	15.9
	1.9	5.2	−3.2	1.6
	20.3	9.4	13.9	17.5
	0.0	0.0	0.0	0.2
	60.1	45.3	41.3	52.3
	60.1	45.3	41.3	52.2
	−0.3	0.7	−0.1	0.3
	59.8	46.0	41.2	52.6
	60.1	45.3	41.3	52.3
Per share
	₹9.83	₹7.41	₹6.75	₹8.55
	₹9.83	₹7.41	₹6.75	₹8.55
Other comprehensive income — detail
	−0.3	0.7	−0.1	0.3
	—	—	—	0.4
	0.3	−0.7	0.1	0.1
	−0.3	0.7	−0.1	52.6
Per share — as-filed variants
	₹9.83	₹7.41	₹6.75	₹8.55
	₹9.83	₹7.41	₹6.75	₹8.55
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	345	287	282	292
	81.6%	81.2%	82.4%	81.0%
Adjusted (ex-exceptional items) — derived
	80.4	54.5	74.3	69.6
	0.0	0.3	−19.1	0.0
	60.1	45.1	55.5	52.3
	₹9.83	₹7.37	₹9.08	₹8.55

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

CORONA₹2,200.60

CORONA Remedies Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersERIS MANKIND APLLTD ALIVUS AKUMS AGARWALEYE HCG ADVENZYMESMcap ₹13,459 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	361.1	342.4	353.1	422.4
Other Income	2.3	2.2	4.1	3.2
Total Income	363.4	344.7	357.2	425.6
Expenses
+ Cost of Materials Consumed	25.9	24.8	27.7	32.7
+ Purchases of Stock-in-Trade	28.1	41.2	46.3	57.2
+ Changes in Inventories	14.6	-5.7	-7.8	-12.3
+ Employee Benefit Expense	103.0	95.9	106.6	122.1
+ Finance Costs	1.9	1.7	1.4	2.7
+ Depreciation & Amortisation	9.2	9.5	10.3	13.2
+ Other Expenses	111.0	103.1	118.2	129.7
Total Expenses	293.8	270.4	302.7	345.2
EBITDA	78.5	83.2	62.0	93.1
EBIT	69.3	73.7	51.7	79.9
Profit
PBT before Exceptional Items	69.6	74.3	54.5	80.4
+ Exceptional Items	0.0	-19.1	0.3	0.0
Pretax Income	69.6	55.2	54.7	80.4
+ Current Tax	15.9	17.1	4.2	18.4
+ Deferred Tax	1.6	-3.2	5.2	1.9
Tax Expense	17.5	13.9	9.4	20.3
+ Share of Associates & JVs	0.2	0.0	0.0	0.0
Net Income	52.3	41.3	45.3	60.1
+ Net Income — Continuing Ops	52.2	41.3	45.3	60.1
+ Other Comprehensive Income	0.3	-0.1	0.7	-0.3
Total Comprehensive Income	52.6	41.2	46.0	59.8
Net Income to Common	52.3	41.3	45.3	60.1
Per Share
Basic EPS	8.55	6.75	7.41	9.83
Diluted EPS	8.55	6.75	7.41	9.83
Other Comprehensive Income — detail
+ Other Comprehensive Income	0.3	-0.1	0.7	-0.3
+ Items NOT to be Reclassified to P&L	0.4	—	—	—
+ Tax on Items NOT to be Reclassified	0.1	0.1	-0.7	0.3
Comprehensive Income — Owners of Parent	52.6	-0.1	0.7	-0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	8.55	6.75	7.41	9.83
Diluted EPS — Continuing Operations	8.55	6.75	7.41	9.83
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	292.5	282.2	286.9	344.9
Gross Margin %	80.99	82.40	81.24	81.65
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	69.6	74.3	54.5	80.4
− Exceptional Items (reconciliation)	0.0	-19.1	0.3	0.0
Net Income Adj (tax-effected)	52.3	55.5	45.1	60.1
EPS Adj	8.55	9.08	7.37	9.83
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00
Paid Up Equity Capital	61.2	61.2	61.2	61.2

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

CORONA Remedies Q2 FY27 results date

CORONA Remedies (NSE: CORONA) will announce its Q2 FY27 results (July–September 2026) on Friday, 30 October 2026, according to the board-meeting notice it filed on 16 October 2026. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit was ₹60.1 crore, up 32.6% from ₹45.3 crore in Q4 FY26. Revenue from operations was ₹422 crore, up 19.6% from the previous quarter.

Board-meeting notice filed: 16 October 2026
Q2 FY26 results (a year earlier): 2 January 2026
Q1 FY27 results (the latest): 31 July 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 30 October 2026Friday · notice filed 16 Oct
Q1 FY27 net profit: ₹60.1 Cr+32.6% vs Q4 FY26
Q1 FY27 revenue: ₹422 Cr+19.6% vs Q4 FY26
Q1 FY27 operating margin: 18.9%+4.3 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹52.3 CrRevenue ₹361 Cr
Q1 FY27 EPS (basic): ₹9.83

Questions

When will CORONA Remedies announce its Q2 FY27 results?

On 30 October 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 16 October 2026). Last year it reported Q2 FY26 on 2 January 2026.

What will CORONA Remedies' Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit was ₹52.3 crore and revenue from operations ₹361 crore. The latest quarter, Q1 FY27, had a net profit of ₹60.1 crore and revenue of ₹422 crore.

How has CORONA Remedies' profit changed over the last four quarters?

Net profit by quarter: ₹52.3 crore in Q2 FY26, ₹41.3 crore in Q3 FY26, ₹45.3 crore in Q4 FY26 and ₹60.1 crore in Q1 FY27. That is ₹199 crore over the four quarters. Revenue from operations: ₹361 crore, ₹342 crore, ₹353 crore and ₹422 crore.

What were CORONA Remedies' Q1 FY27 results?

Consolidated net profit was ₹60.1 crore, up 32.6% from ₹45.3 crore in Q4 FY26. Revenue from operations was ₹422 crore, up 19.6% from the previous quarter.

What was CORONA Remedies' net profit in FY26?

Consolidated net profit was ₹185 crore in FY26 (April 2025–March 2026).

What was CORONA Remedies' revenue in FY26?

Revenue from operations was ₹1,403 crore in FY26 (April 2025–March 2026).

Where do these CORONA Remedies figures come from?

From CORONA Remedies' own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.